• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

    2/9/23 11:30:23 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBYI alert in real time by email
    SC 13G/A 1 tv01731-pumabiotechnologyinc.htm SCHEDULE 13G/A pumabiotechnologyinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 9)*

    Name of issuer:  Puma Biotechnology Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  74587V107

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  74587V107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    3,574,479

    8.  SHARED DISPOSITIVE POWER

    14,443

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,588,922

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.86%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Puma Biotechnology Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10880 Wilshire Boulevard, Suite 2150
    Los Angeles, CA 90024-4101

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    74587V107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $PBYI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBYI

    DatePrice TargetRatingAnalyst
    9/28/2021$11.00Neutral → Buy
    Citigroup
    9/28/2021Neutral → Buy
    Citigroup
    8/6/2021$13.00 → $6.00Sector Perform
    RBC Capital
    8/6/2021$9.00 → $8.00Sell
    Goldman Sachs
    More analyst ratings

    $PBYI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a

      5/6/25 5:15:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

      ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ:PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzb

      4/30/25 6:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Puma Biotech. upgraded by Citigroup with a new price target

      Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00

      9/28/21 7:42:41 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology upgraded by Citigroup

      Citigroup upgraded Puma Biotechnology from Neutral to Buy

      9/28/21 4:54:51 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Puma Biotechnology with a new price target

      RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously

      8/6/21 10:44:06 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Nougues Maximo F was granted 61,456 shares, increasing direct ownership by 40% to 213,751 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:58:40 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Ludwig Jeffrey Jerome was granted 47,841 shares, increasing direct ownership by 44% to 156,792 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:55:59 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hunt Douglas M was granted 48,117 shares, increasing direct ownership by 39% to 172,711 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:53:52 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Financials

    Live finance-specific insights

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of

      4/24/25 4:11:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

      2/27/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Puma Biotechnology Inc

      SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      3/29/24 10:40:57 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/14/24 8:19:11 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/13/24 5:12:15 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Leadership Updates

    Live Leadership Updates

    See more
    • Puma Biotechnology to Join Russell 3000 Index

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

      5/28/24 9:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

      Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

      11/17/22 4:15:00 PM ET
      $EPIX
      $PBYI
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

      8/15/22 5:00:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    SEC Filings

    See more
    • Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/9/25 8:57:31 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Puma Biotechnology Inc

      10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:41:37 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:20:43 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care